The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.

Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.

The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.

Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.

Dermatology Times previews the research, clinical updates, late-breaking data, and therapeutic advances to watch at EADV 2026 in Vienna.

Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.

Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.

The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.